SCHEMBL21448024

SCHEMBL21448024

Cc1cccc2c1C(C)(C)CN(C)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 8/20 0.41
SLC6A2 P23975 7/20 0.41
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTR2B P41595 3/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
SLC6A4 P31645 6/20 0.35
BTK Q06187 1/20 0.35
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
ADRA2A P08913 2/20 0.31
OPRM1 P35372 2/20 0.31
HTR5A P47898 1/20 0.31
CHRM2 P08172 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21448033 0.80 MAOA (0.41) SLC6A3SLC6A2MAOAMAOBALDH1A1
SCHEMBL21448023 0.80 ADRA2A (0.43) SLC6A3SLC6A2MAOAMAOBALDH1A1
SCHEMBL7652793 0.80 MAOA (0.37) SLC6A3SLC6A2MAOAMAOBALDH1A1
SCHEMBL20180485 0.76 SLC6A2 (0.34) SLC6A3SLC6A2ALDH1A1SMN1; SMN2SLC6A4
SCHEMBL20648805 0.74 ADRA2C (0.31)
SCHEMBL7662442 0.74 TDP1 (0.41) ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL17771729 0.73 RECQL (0.37) ALDH1A1HPGDSMN1; SMN2HTR2BHTR2A
SCHEMBL9917028 0.73 MAOA (0.45) MAOAMAOBSMN1; SMN2HTR2BHTR2A
SCHEMBL29676365 0.73 MAOA (0.45) MAOAMAOBSMN1; SMN2HTR2BHTR2A
SCHEMBL20889893 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones Impact Therapeutics (Shanghai), Inc (CN) 2022-05-31 US disclosed
US-11345710-B2 Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof Impact Therapeutics (Shanghai), Inc (CN) 2022-05-31 US disclosed
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones IMPACT THERAPEUTICS, INC (CN) 2020-07-07 US disclosed
US-20200131192-A1 IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF IMPACT THERAPEUTICS, INC. (CN) 2020-04-30 US disclosed
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2019-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131192-A1 IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF WEE1, WEE2, CCNE1 SLC6A3 2974/4885SLC6A2 3819/4885MAOA 3856/4885
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 SLC6A3 2847/4885SLC6A2 3865/4885MAOA 4170/4885
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 SLC6A3 2847/4885SLC6A2 3865/4885MAOA 4170/4885
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 SLC6A3 2847/4885SLC6A2 3865/4885MAOA 4170/4885
US-11345710-B2 Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof WEE1, WEE2, CCNE1 SLC6A3 2974/4885SLC6A2 3819/4885MAOA 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.